PDT Partners’s Biocept, Inc. BIOC Stock Holding History

PDT Partners’s Portfolio BIOC Stock Details BIOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,188	Closed	-$83K	–	1212
2022 Q1	$83K	Sell	1,188 -9	-0.8%	-$707	0.01%	882
2021 Q4	$130K	Buy	+1,197	New	+$138K	0.01%	802

Other funds holding BIOC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

PDT Partners's BIOC Position: Q2 2022 in Review

PDT Partners sold out of Biocept, Inc. (BIOC) in Q2 2022, closing a stake of 1,188 shares — an estimated $83K sold.

PDT Partners first reported a position in BIOC in Q4 2021 and held it in 2 quarters. The position peaked at $130K in Q4 2021. 27 funds tracked by Wall St. Rank hold BIOC as of Q2 2022.

PDT Partners reported no remaining Biocept, Inc. position as of Q2 2022 after selling out during the quarter.
PDT Partners sold 1,188 Biocept, Inc. shares in Q2 2022, an estimated $83K.
PDT Partners first reported a position in Biocept, Inc. in Q4 2021 and held it in 2 quarters.
PDT Partners's Biocept, Inc. position peaked at $130K in Q4 2021.
27 funds tracked by Wall St. Rank held Biocept, Inc. as of Q2 2022.

Based on PDT Partners's 13F filing for Q2 2022, filed 15 Aug 2022.